Table 1.
The reproducibility study of aptamer-modified microfluidic chips.
| Object | ID | Test 1 | Test 2 | Test 3 | Std | CV | |
|---|---|---|---|---|---|---|---|
| Ap1 | Patient | P1 | 4 | 4 | 5 | 0.58 | 13.32% |
| P2 | 7 | 6 | 4 | 1.53 | 26.96% | ||
| P3 | 4 | 5 | 6 | 1.00 | 20.00% | ||
| Average | – | – | – | 1.04 | 20.1% | ||
| Healthy donor | H1 | 0 | 0 | 0 | – | – | |
| H2 | 0 | 0 | 0 | – | – | ||
| H3 | 0 | 0 | 0 | – | – | ||
| Cocktail A | Patient | P4 | 10 | 11 | 8 | 1.53 | 15.80% |
| P5 | 4 | 7 | 6 | 1.53 | 26.96% | ||
| P6 | 8 | 10 | 7 | 1.53 | 18.33% | ||
| Average | – | – | – | 1.53 | 20.4% | ||
| Healthy donor | H4 | 0 | 0 | 0 | – | – | |
| H5 | 0 | 0 | 0 | – | – | ||
| H6 | 1 | 0 | 0 | – | – | ||
| Cocktail B | Patient | P10 | 16 | 14 | 19 | 2.52 | 15.41% |
| P11 | 11 | 8 | 10 | 1.53 | 15.80% | ||
| P12 | 12 | 9 | 13 | 2.08 | 18.37% | ||
| Average | – | – | – | 2.04 | 16.5% | ||
| Healthy donor | H10 | 0 | 0 | 0 | – | – | |
| H11 | 0 | 0 | 0 | – | – | ||
| H12 | 0 | 0 | 0 | – | – | ||
| Cocktail C | Patient | P7 | 7 | 7 | 8 | 0.58 | 7.87% |
| P8 | 14 | 17 | 16 | 1.53 | 9.75% | ||
| P9 | 12 | 13 | 14 | 1.00 | 7.69% | ||
| Average | – | – | – | 1.04 | 8.4% | ||
| Healthy donor | H7 | 0 | 0 | 0 | – | – | |
| H8 | 0 | 0 | 1 | – | – | ||
| H9 | 0 | 0 | 0 | – | – |
Statistically significant differences were observed between CTC counts of NSCLC patients and healthy donors, i.e., Ap1 (t-test, P = 0.006), Cocktail A (t-test, P = 0.021), Cocktail B (t-test, P = 0.025), and Cocktail C (t-test, P = 0.040).
Abbreviations: Std, standard deviation; CV, coefficient variation.